Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent Surgery.
NEJM EVIDENCE 2022;
1:EVIDoa2100047. [PMID:
38319214 DOI:
10.1056/evidoa2100047]
[Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2024]
Abstract
Bentracimab for Ticagrelor Reversal in Patients Undergoing Urgent SurgeryTicagrelor is a reversible oral P2Y12 platelet inhibitor used in patients with many forms of heart and vascular disease. Because patients receiving ticagrelor may bleed or need emergent surgery, bentracimab was studied as a ticagrelor reversal agent. In this study in 150 patients, treatment had a significant salutary impact on laboratory measured platelet function. Adjudicated hemostasis was achieved in over 90% of patients, most of whom had cardiac surgery; thrombotic events occurred in just over 5% of treated patients.
Collapse